98%
921
2 minutes
20
Background: A consistent proportion of individuals at risk for Alzheimer's disease show intact cognition regardless of the extensive accumulation of amyloid-β (Aβ) peptide in their brain. Several pieces of evidence indicate that overactivation of brain regions negative for Aβ can compensate for the underactivation of Aβ-positive ones to preserve cognition, but the underlying synaptic changes are still unexplored.
Methods: Using Golgi staining, we investigate how dendritic spines rearrange following contextual fear conditioning (CFC) in the hippocampus and amygdala of presymptomatic Tg2576 mice, a genetic model for Aβ accumulation. A molecular biology approach combined with intrahippocampal injection of a γ-secretase inhibitor evaluates the impact of Aβ fluctuations on spine rearrangements.
Results: Encoding of CFC increases Aβ oligomerization in the hippocampus but not in the amygdala of Tg2576 mice. The presence of Aβ oligomers predicts vulnerability to network dysfunctions, as low c-Fos activation and spine maturation are detected in the hippocampus of Tg2576 mice upon recall of CFC memory. Rather, enhanced c-Fos activation and new spines are evident in the amygdala of Tg2576 mice compared with wild-type control mice. Preventing Aβ increase in the hippocampus of Tg2576 mice restores CFC-associated spine changes to wild-type levels in both the hippocampus and amygdala.
Conclusions: Our study provides the first evidence of neural compensation consisting of enhanced synaptic activity in brain regions spared by Aβ load. Furthermore, it unravels an activity-mediated feedback loop through which neuronal activation during CFC encoding favors Aβ oligomerization in the hippocampus and prevents synaptic rearrangements in this region.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.biopsych.2018.10.018 | DOI Listing |
Alzheimers Res Ther
August 2025
Department of Neurology, MassGeneral Institute of Neurodegenerative Diseases, Massachusetts General Hospital and Harvard Medical School, Charlestown Boston, MA, 02129, USA.
Background: Alzheimer's disease (AD) is characterized by amyloid-beta (Aβ) accumulation, leading to the formation of neurotoxic soluble oligomers (AβOs) that impair calcium homeostasis in neurons and astrocytes. Aducanumab, a fully human monoclonal antibody targeting aggregated Aβ, has been approved for AD treatment due to its ability to reduce amyloid plaque burden. However, its specificity toward different AβO species and its functional impact on calcium homeostasis remain unclear.
View Article and Find Full Text PDFFluids Barriers CNS
July 2025
Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
Alzheimer's disease (AD), marked by amyloid-beta (Aβ) plaques and tau tangles, involves cerebral amyloid angiopathy (CAA), which may compromise blood-brain barrier (BBB) integrity. However, the extent and nature of BBB disruption in AD remain unclear. This study assessed BBB permeability in Tg2576 AD mice by evaluating unidirectional paracellular transport from blood to brain following intravenous injection of the stable isotope-labeled marker [¹³C₁₂]sucrose.
View Article and Find Full Text PDFNeurobiol Dis
September 2025
Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN 46202, USA; Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536, USA. Electronic address:
Cerebral amyloid angiopathy (CAA) is an extremely common pathology of Alzheimer's disease (AD) included under vascular contributions to cognitive impairment and dementia (VCID). CAA has been reported in 78-98 % of AD cases and has clinical significance when considering side effects that arise when using amyloid targeting immunotherapies. Despite its prevalence, studies addressing CAA mechanisms have been scarce and there are clear gaps in our understanding of how CAA progresses.
View Article and Find Full Text PDFJ Neural Transm (Vienna)
June 2025
Department of Pharmacology and Croatian Institute of Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, metabolic dysregulation, brain insulin resistance, and oxidative stress. Familial AD (fAD) models, like the Tg2576 mice, offer insights into early-onset AD; however, their relevance to sporadic AD remains limited. This study investigated brain insulin signalling and oxidative stress in Tg2576 mice at presymptomatic (7-month) and mild AD (12-month) stages, focusing on the hippocampus and hypothalamus.
View Article and Find Full Text PDFCells
June 2025
Department of Biomedical Sciences, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
Most approved drugs for Alzheimer's disease (AD) are indicated for early to moderate stages and primarily target amyloid-beta or neurotransmitter systems. While these treatments may slow cognitive decline, they do not halt disease progression and are often limited by high cost and modest efficacy. Natural compounds are increasingly being explored as alternative interventions.
View Article and Find Full Text PDF